ZYNE logo

Zynerba Pharmaceuticals (ZYNE) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

05 August 2015

Indexes:

Not included

Description:

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. As of October 10, 2023, Zynerba Pharmaceuticals, Inc. operates as a subsidiary of Harmony Biosciences Holdings, Inc.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Nov 14, 2023

Recent annual earnings:

Mar 01, 2022
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

16 Aug '23 Canaccord Genuity
Hold
15 Aug '23 HC Wainwright & Co.
Neutral
23 June '22 Canaccord Genuity
Buy
01 July '20 Needham
Hold
28 May '20 Cantor Fitzgerald
Overweight
21 Oct '19 Needham
Buy
30 Apr '19 Roth Capital
Buy
21 Sept '18 Cantor Fitzgerald
Overweight
03 Aug '18 Canaccord Genuity
Buy
29 Jan '18 Ladenburg Thalmann
Buy

Screeners with ZYNE included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

Why Is Zynerba Pharmaceuticals (ZYNE) Stock Up 270% Today?
Why Is Zynerba Pharmaceuticals (ZYNE) Stock Up 270% Today?
Why Is Zynerba Pharmaceuticals (ZYNE) Stock Up 270% Today?
ZYNE
InvestorPlace14 August 2023

In a stunning turn of the tables, beleaguered cannabinoid therapeutics developer Zynerba Pharmaceuticals (NASDAQ: ZYNE ) skyrocketed on Monday following an announcement early this morning of a buyout. Specifically, Harmony Biosciences (NASDAQ: HRMY ) — which focuses on innovative therapies for patients with rare neurological diseases — will acquire Zynerba.

Zynerba Pharma stock rockets on premium priced Harmony deal
Zynerba Pharma stock rockets on premium priced Harmony deal
Zynerba Pharma stock rockets on premium priced Harmony deal
ZYNE
Proactive Investors14 August 2023

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) stock rocketed three-times higher as investors are set to pocket a bumper payday as Harmony Biosciences (NASDAQ:HRMY) agreed to buy the cannabinoid therapies company for US$200 million. Harmony is to pay US$60 million, US$1.1059 per share, in cash cash upfront plus up to US$140 million in contingent future payments tied to clinical, regulatory and sales milestones.

Zynerba (ZYNE) Upgraded to Buy: What Does It Mean for the Stock?
Zynerba (ZYNE) Upgraded to Buy: What Does It Mean for the Stock?
Zynerba (ZYNE) Upgraded to Buy: What Does It Mean for the Stock?
ZYNE
Zacks Investment Research29 June 2023

Zynerba (ZYNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
ZYNE
GlobeNewsWire20 June 2023

DEVON, Pa., June 20, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference being held June 26, 2023.

FAQ

  • What is the primary business of Zynerba Pharmaceuticals?
  • What is the ticker symbol for Zynerba Pharmaceuticals?
  • Does Zynerba Pharmaceuticals pay dividends?
  • What sector is Zynerba Pharmaceuticals in?
  • What industry is Zynerba Pharmaceuticals in?
  • What country is Zynerba Pharmaceuticals based in?
  • When did Zynerba Pharmaceuticals go public?
  • Is Zynerba Pharmaceuticals in the S&P 500?
  • Is Zynerba Pharmaceuticals in the NASDAQ 100?
  • Is Zynerba Pharmaceuticals in the Dow Jones?
  • When was Zynerba Pharmaceuticals's last earnings report?
  • When does Zynerba Pharmaceuticals report earnings?
  • Should I buy Zynerba Pharmaceuticals stock now?

What is the primary business of Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. As of October 10, 2023, Zynerba Pharmaceuticals, Inc. operates as a subsidiary of Harmony Biosciences Holdings, Inc.

What is the ticker symbol for Zynerba Pharmaceuticals?

The ticker symbol for Zynerba Pharmaceuticals is NASDAQ:ZYNE

Does Zynerba Pharmaceuticals pay dividends?

No, Zynerba Pharmaceuticals does not pay dividends

What sector is Zynerba Pharmaceuticals in?

Zynerba Pharmaceuticals is in the Healthcare sector

What industry is Zynerba Pharmaceuticals in?

Zynerba Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry

What country is Zynerba Pharmaceuticals based in?

Zynerba Pharmaceuticals is headquartered in United States

When did Zynerba Pharmaceuticals go public?

Zynerba Pharmaceuticals's initial public offering (IPO) was on 05 August 2015

Is Zynerba Pharmaceuticals in the S&P 500?

No, Zynerba Pharmaceuticals is not included in the S&P 500 index

Is Zynerba Pharmaceuticals in the NASDAQ 100?

No, Zynerba Pharmaceuticals is not included in the NASDAQ 100 index

Is Zynerba Pharmaceuticals in the Dow Jones?

No, Zynerba Pharmaceuticals is not included in the Dow Jones index

When was Zynerba Pharmaceuticals's last earnings report?

Zynerba Pharmaceuticals's most recent earnings report was on 14 November 2023

When does Zynerba Pharmaceuticals report earnings?

The date for Zynerba Pharmaceuticals's next earnings report has not been announced yet

Should I buy Zynerba Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions